期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Screening for a^(177)Lu-labeled CA19–9 monoclonal antibody via PET imaging for colorectal cancer therapy 被引量:1
1
作者 Jing Wang liangang zhuo +5 位作者 Peng Zhao Wei Liao Hongyuan Wei Yuchuan Yang Shuming Peng Xia Yang 《Chinese Chemical Letters》 SCIE CAS CSCD 2022年第7期3502-3506,共5页
Carbohydrate antigen 19–9(CA19–9)with multi epitopes relatively high expresses on colorectal cancer(CRC)cells,making it an attractive target for developing radioimmunotherapy(RIT)for CRC.The lutetium-177(^(177)Lu)la... Carbohydrate antigen 19–9(CA19–9)with multi epitopes relatively high expresses on colorectal cancer(CRC)cells,making it an attractive target for developing radioimmunotherapy(RIT)for CRC.The lutetium-177(^(177)Lu)labeled monoclonal antibodies(mA bs)can selectively bind the corresponding antigens and release targeted cytotoxic radiation,which could induce cell apoptosis and reduce the drug-induced resistance.Here,a series of CA19–9 m Abs were labeled with zirconium-89(^(89)Zr),and one with high tumor uptake was screened via PET imaging,which has potential application for the diagnosis of CRC.Then the screened m Ab(C003)labeled with^(177)Lu was utilized for CA19–9 targeted RIT,which presents a significant suppression effect on the growth of colo205 xenografts than immunotherapy alone.Meanwhile,the side effects of ^(177)Lu-DOTA-C003 are limited according to the results of in vivo study.Both89Zr-DFO-C003for CRC immune-PET imaging and ^(177)Lu-DOTA-C003 for RIT against CRC exhibit good potential in clinical applications. 展开更多
关键词 Lutetium-177 CA19–9 Monoclonal antibody Colorectal cancer RADIOIMMUNOTHERAPY
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部